news.buyenne.com

(credit: Alpha six)

Cloud backup provider Backblaze has published the latest data it has accumulated about the reliability of the hard drives it uses. In the first quarter of the year, the company passed more than a billion hours of aggregate drive usage since it started tracking reliability in April 2013.

HGST's drives have long stood out as the most reliable, and that trend continues. Their failure rate is remarkably low; even after three years in service, the 3TB and 4TB units have annualized failure rates of just 0.81 percent and 1.03 percent, respectively. 2TB units, which last quarter were already on average more than 5 years old, have seen a small increase in failure rate—1.57 percent, compared to 1.15 percent a year ago—but still show extraordinary reliability considering their age.

After some bad experiences with certain models, and annualized failure rates in some cases approaching 30 percent, Seagate's performance is also solid. Backblaze's most common disk type is a 4TB Seagate unit, with nearly 35,000 of the drives in use, and those are demonstrating at a failure rate of 2.90 percent.

(credit: Alan Rockefeller)

Psilocybin, the psychedelic compound in ‘magic’ mushrooms, may be an effective way to treat depression in patients that have seen no benefit from other, standard forms of treatment, early results suggest.

In a pilot study involving just 12 people with treatment-resistant depression, two doses of the mushroom compound cleared symptoms in eight participants—67 percent—after one week. After three months and no other doses, seven participants still reported reduced depressive symptoms, including five—42 percent—who reported complete remission of their depression.

But the finding, published Tuesday in the Lancet Psychiatry, is just a first step to assess safety of using the hallucinogenic drug. With such a small study, no controls, and non-randomized participants, it is not possible to determine if the promising efficacy results will stand.

(credit: Alan Rockefeller)

Psilocybin, the psychedelic compound in ‘magic’ mushrooms, may be an effective way to treat depression in patients that have seen no benefit from other, standard forms of treatment, early results suggest.

In a pilot study involving just 12 people with treatment-resistant depression, two doses of the mushroom compound cleared symptoms in eight participants—67 percent—after one week. After three months and no other doses, seven participants still reported reduced depressive symptoms, including five—42 percent—who reported complete remission of their depression.

But the finding, published Tuesday in the Lancet Psychiatry, is just a first step to assess safety of using the hallucinogenic drug. With such a small study, no controls, and non-randomized participants, it is not possible to determine if the promising efficacy results will stand.